Latest Licensing Agreements News

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

FirstWave Cloud Technology has affirmed its compliance with ASX rules following an inquiry into the timing of its $1.85 million Services Australia software licence announcement, confirming the information was material and promptly disclosed.

Avecho Biotechnology has wrapped up the treatment phase for its pivotal Phase III insomnia trial involving 244 participants, setting the stage for an interim efficacy analysis expected in late June 2026.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

FirstWave Cloud Technology delivered a strong Q3 FY26 with a $1.40m net operating cash inflow and a major two-year licensing agreement with Mexico’s Banobras bank, marking a key milestone in its AI compliance pivot.

ARN Media reported a 10% revenue decline in FY25 but accelerated digital growth and cost savings, while defending ongoing legal disputes with former talent.

BrainChip Holdings has signed a global IP license agreement with ASICLAND, enabling integration of its Akida neuromorphic AI technology into custom SoC designs with a royalty-based revenue model.

X2M Connect is accelerating its transition to a high-margin SaaS model while trimming debt and growing its footprint across Asia-Pacific and the Middle East.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

CurveBeam AI reported stable device orders but faces regulatory delays for FDA and China clearances, while securing a A$4 million investment from WEGO Orthopaedics and advancing clinical collaborations with robotic surgery systems.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.